PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY AGREEMENT

CONVEYING PARTY DATA

Name	Execution Date
GOOD START GENETICS, INC.	04/25/2013

RECEIVING PARTY DATA

Name:	BRIDGE BANK, NATIONAL ASSOCIATION
Street Address:	55 ALMADEN BOULEVARD
City:	SAN JOSE
State/Country:	CALIFORNIA
Postal Code:	95113

PROPERTY NUMBERS Total: 24

Property Type	Number
Patent Number:	8209130
Application Number:	61182086
Application Number:	61789164
Application Number:	61624778
Application Number:	61621779
Application Number:	61707495
Application Number:	61723550
Application Number:	61723508
Application Number:	61784624
Application Number:	13494616
Application Number:	13081660
Application Number:	13488142
Application Number:	13266862
Application Number:	13077169
Application Number:	13616788

OP $960.00 8209130

Application Number:	13448961
Application Number:	13667575
Application Number:	13439508
PCT Number:	US2010001293
PCT Number:	US2012029790
PCT Number:	US2012055362
PCT Number:	US2013032885
PCT Number:	US2011065098
PCT Number:	US2013033435

CORRESPONDENCE DATA

Fax Number: 6173506878

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 6173506800

Email: trademarks@gesmer.com

Correspondent Name: Susan M. Mulholland/GESMER UPDEGROVE LLP

Address Line 1:   40 Broad Street

Address Line 4:   Boston, MASSACHUSETTS 02109

ATTORNEY DOCKET NUMBER:	BRIDGE BANK PATENT LIENS
NAME OF SUBMITTER:	Susan M. Mulholland
Signature:	/sm mulholland/
Date:	04/30/2013

Total Attachments: 10
source=Bridge Bank - Good Start Genetics Security Lien#page1.tif
source=Bridge Bank - Good Start Genetics Security Lien#page2.tif
source=Bridge Bank - Good Start Genetics Security Lien#page3.tif
source=Bridge Bank - Good Start Genetics Security Lien#page4.tif
source=Bridge Bank - Good Start Genetics Security Lien#page5.tif
source=Bridge Bank - Good Start Genetics Security Lien#page6.tif
source=Bridge Bank - Good Start Genetics Security Lien#page7.tif
source=Bridge Bank - Good Start Genetics Security Lien#page8.tif
source=Bridge Bank - Good Start Genetics Security Lien#page9.tif
source=Bridge Bank - Good Start Genetics Security Lien#page10.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT
(Good Start Genetics, Inc.)

This INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of April 25, 2013 (the "Agreement") between BRIDGE BANK, NATIONAL ASSOCIATION ("Lender") and GOOD START GENETICS, INC. ("Grantor") is made with reference to the Loan and Security Agreement, dated December 21, 2012, as amended by that certain Amendment No. 1 to Loan and Security Agreement, dated as of the date hereof (as amended from time to time, collectively the "Loan Agreement'), between Lender and Grantor. Terms defined in the Loan Agreement have the same meaning when used in this Agreement.

For good and valuable consideration, receipt of which is hereby acknowledged, Grantor hereby covenants and agrees as follows:

To secure the Obligations under the Loan Agreement, Grantor grants to Lender a security interest in all right, title, and interest of Grantor in any of the following, whether now existing or hereafter acquired or created in any and all of the following property (collectively, the "Intellectual Property Collateral"):

(a) copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held (collectively, the "Copyrights"), including the Copyrights described in Exhibit A;

(b) trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Borrower connected with and symbolized by such trademarks (collectively, the "Trademarks"), including the Trademarks described in Exhibit B;

(c) patents, patent applications and like protections including without limitation improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same (collectively, the "Patents"), including the Patents described in Exhibit C;

(d) mask work or similar rights available for the protection of semiconductor chips or other products (collectively, the "Mask Works");

(e) trade secrets, and any and all intellectual property rights in computer software and computer software products;

(f) design rights;

(g) claims for damages by way of past, present and future infringement of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works, and all license fees and royalties arising from such use to the extent permitted by such license or rights;

809255.3

(i) amendments, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

All of the Lender's rights, powers and remedies set forth in the Loan Agreement are incorporated herein by reference. The rights of Lender with respect to the security interests granted hereunder are in addition to those set forth in the Loan Agreement, and those which are now or hereafter available to Lender as a matter of law or equity. Each right, power and remedy of Lender provided for in the Loan Agreement, and herein by incorporated reference, or now or hereafter existing at law or in equity, shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein, and the exercise by Lender of any one or more of such rights, powers or remedies does not preclude the simultaneous or later exercise by Lender of any other rights, powers or remedies.

(Remainder of the page is blank. A signature appears on the following page.)

2

809255.3

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

GRANTOR:

GOOD START GENETICS, INC.

By: _____

Name: Don Hardison

Title: President and Chief Executive Officer

LENDER:

BRIDGE BANK, NATIONAL ASSOCIATION

By: _____

Name: Charles A. Wehr

Title: Relationship Manager

Address for Notices:
Attn: Jean Franchi
237 Putnam Avenue
Cambridge, Massachusetts 02139
Tel: (617) 714-0814
Fax: (617) 714-0801

Address for Notices:
Attn: Michael Field
55 Almaden Boulevard, Suite 100
San Jose, California 95113
Tel: (408) 556-6501
Fax:(408) 282-1681

and

Attn: Charles A. Wehr
One Broadway, 14th Floor
Cambridge, Massachusetts 02142
Tel: (617) 995-1312

[Good Start: Signature page to Intellectual Property Security Agreement – April 2013]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

GRANTOR:

GOOD START GENETICS, INC.

By: _____
Name: Don Hardison
Title: President and Chief Executive Officer

LENDER:

BRIDGE BANK, NATIONAL ASSOCIATION

By: _____
Name: Charles A. Wehr
Title: Relationship Manager

Address for Notices:
Attn: Jean Franchi
237 Putnam Avenue
Cambridge, Massachusetts 02139
Tel: (617) 714-0814
Fax: (617) 714-0801

Address for Notices:
Attn: Michael Field
55 Almaden Boulevard, Suite 100
San Jose, California 95113
Tel: (408) 556-6501
Fax:(408) 282-1681

and

Attn: Charles A. Wehr
One Broadway, 14th Floor
Cambridge, Massachusetts 02142
Tel: (617) 995-1312

[Good Start: Signature page to Intellectual Property Security Agreement – April 2013]

Exhibit A
COPYRIGHTS

None.

(Remainder of the page is blank.)

4

EXHIBIT B

TRADEMARKS

Application Number	Mark	Filing Date
Serial No. 85093437 Registration No. 4096815	GOOD START GENETICS	27-July-2010
Serial No. AU1405764	GOOD START GENETICS	27-Jan-2011
Serial No. CA1512721	GOOD START GENETICS	26-Jan-2011
Serial No. CN9066430	GOOD START GENETICS	27-Jan-2011
Serial No. EC9689522	GOOD START GENETICS	27-Jan-2011
Serial No. JP2011-005125	GOOD START GENETICS	27-Jan-2011
Serial No. 85/599068	GOODSTART SELECT	16-Apr-2012
Serial No. 85/599066	GSG LABSOLUTIONS	16-Apr-2012
Serial No. 85/599063	GSG SOLUTIONS	16-Apr-2012
Serial No. 85/599051	GIVING THE NEXT GENERATION A GOOD START	16-Apr-2012
Serial No. 85/600801	HELPING TO GIVE THE NEXT GENERATION A GOOD START	18-Apr-2012
Serial No. 85/683029	GOODSTART TESTSELECT	20-Jul-2012

(Remainder of the page is blank.)

5

809255.3

EXHIBIT C

PATENTS and PATENT APPLICATIONS

Patent Applications:

Patent Application Number	Country	Filing Date	Title	Attorney Docket Number	Status	Priority
61/426,817	US	23-Dec-10	METHODS FOR MAINTAINING THE INTEGRITY AND IDENTIFICATION OF A NUCLEIC ACID TEMPLATE IN A MULTIPLEX SEQUENCING REACTION	GSGE-001/00US	Expired	
13/081,660	US	07-Apr-11	METHODS FOR MAINTAINING THE INTEGRITY AND IDENTIFICATION OF A NUCLEIC ACID TEMPLATE IN A MULTIPLEX SEQUENCING REACTION	GSGE-001/01US	Pending	61/426,817
PCT/US11/65 098	PCT	15-Dec-11	METHODS FOR MAINTAINING THE INTEGRITY AND IDENTIFICATION OF A NUCLEIC ACID TEMPLATE IN A MULTIPLEX SEQUENCING REACTION	GSGE-001/01WO	Pending	61/426,817; 13/081,660
61/174,470	US	30-Apr-09	METHOD FOR REDUCING REPRESENTATIONAL BIAS IN MULTIPLEX AMPLIFICATION OF NUCLEIC ACIDS	GSGE-002/00US	Expired	
61/178,923	US	15-May-09	METHODS AND COMPOSITIONS FOR ENHANCING THE SENSITIVITY OF NUCLEIC ACID ANALYSIS	GSGE-003/00US	Expired	
61/179,358	US	18-May-09	METHODS AND COMPOSITIONS FOR REDUCING DIAGNOSTIC ERRORS ASSOCIATED WITH BIAS IN PREPARATIONS OF NUCLEIC ACIDS	GSGE-004/00US	Expired	
61/182,089	US	28-May-09	EVALUATIONS OF TARGET LENGTH IN NUCLEIC ACID CAPTURE-BASED ASSAYS	GSGE-005/00US	Expired	

809255.3

PCT/US10/01293	PCT	30-Apr-10	METHOD FOR REDUCING REPRESENTATIONAL BIAS IN MULTIPLEX AMPLIFICATION OF NUCLEIC ACIDS	GSGE-002/01WO	Nationalized	61/178,923; 61/179,358; 61/182,086; 61/174,470.
2010242073	AU	30-Apr-10	METHOD FOR REDUCING REPRESENTATIONAL BIAS IN MULTIPLEX AMPLIFICATION OF NUCLEIC ACIDS	GSGE-002/01AU	Pending	61/178,923; 61/179,358; 61/182,086; 61/174,470; PCT/US2010/001293
2760439	CA	30-Apr-10	METHOD FOR REDUCING REPRESENTATIONAL BIAS IN MULTIPLEX AMPLIFICATION OF NUCLEIC ACIDS	GSGE-002/01CA	Published	61/178,923; 61/179,358; 61/182,086; 61/174,470; PCT/US2010/001293
10770071.8	EP	30-Apr-10	METHOD FOR REDUCING REPRESENTATIONAL BIAS IN MULTIPLEX AMPLIFICATION OF NUCLEIC ACIDS	GSGE-002/01EP	Published	61/178,923; 61/179,358; 61/182,086; 61/174,470; PCT/US2010/001293
216054	IL	30-Apr-10	METHOD FOR REDUCING REPRESENTATIONAL BIAS IN MULTIPLEX AMPLIFICATION OF NUCLEIC ACIDS	GSGE-002/01IL	Pending	61/178,923; 61/179,358; 61/182,086; 61/174,470; PCT/US2010/001293
8063/CHENP/2011	IN	30-Apr-10	METHOD FOR REDUCING REPRESENTATIONAL BIAS IN MULTIPLEX AMPLIFICATION OF NUCLEIC ACIDS	GSGE-002/01IN	Pending	61/178,923; 61/179,358; 61/182,086; 61/174,470; PCT/US2010/001293
2012-508490	JP	30-Apr-10	METHOD FOR REDUCING REPRESENTATIONAL BIAS IN MULTIPLEX AMPLIFICATION OF NUCLEIC ACIDS	GSGE-002/01JP	Pending	61/178,923; 61/179,358; 61/182,086; 61/174,470; PCT/US2010/001293
13/266,862	US	28-Oct-11	METHOD FOR REDUCING REPRESENTATIONAL BIAS IN MULTIPLEX AMPLIFICATION OF NUCLEIC ACIDS	GSGE-002/01US	Pending	61/178,923; 61/179,358; 61/182,086; 61/174,470; PCT/US2010/001293

809255.3

61/789,164	US	15-Mar-13	METHODS AND COMPOSITIONS FOR EVALUATING GENETIC MARKERS	GSGE-002/02US	Pending	
13/077,169	US	31-Mar-11	METHODS FOR MAINTAINING THE INTEGRITY AND IDENTIFICATION OF A NUCLEIC ACID TEMPLATE IN A MULTIPLEX SEQUENCING REACTION	GSGE-006/00US	Pending	
PCT/US12/29790	PCT	20-Mar-12	METHODS FOR MAINTAINING THE INTEGRITY AND IDENTIFICATION OF A NUCLEIC ACID TEMPLATE IN A MULTIPLEX SEQUENCING REACTION	GSGE-006/01WO	Pending	13/077,169
13/439,508	US	4-Apr-12	SEQUENCE ASSEMBLY	GSGE-007/00US	Issued; US 8,209,130	
13/494,616	US	13-Jun-12	SEQUENCE ASSEMBLY	GSGE-007/01US	Pending	13/439,508
PCT/US13/33435	US	22-Mar-13	SEQUENCE ASSEMBLY	GSGE-007/01WO	Pending	13/439,508 and 13/494,616
61/548,073	US	17-Oct-11	ANALYSIS METHODS	GSGE-008/00US	Expired	
13/616,788	US	14-Sept-12	ANALYSIS METHODS	GSGE-008/01US	Pending	61/548,073
PCT/US12/55362	PCT	14-Sept-12	ANALYSIS METHODS	GSGE-008/01WO	Pending	61/548,073
61/624,778	US	16-Apr-12	PERFORMANCE OF CAPTURE REACTIONS	GSGE-009/00US	Pending	
13/448,961	US	17-Apr-12	CAPTURE REACTIONS	GSGE-009/01US	Pending	61/624,778
61/621,779	US	9-Apr-12	VARIANT DATABASE	GSGE-010/00US	Pending	
13/667,575	US	2-Nov-12	VARIANT DATABASE	GSGE-010/01US	Pending	61/621,779
PCT/US13/32885	US	19-Mar-13	VARIANT DATABASE	GSGE-010/01WO	Pending	61/621,779 and 13/667,575
61/707,495	US	28-Sept-12	OPTIMIZATION OF BIOMARKER NUMBERS IN SCREENING ASSAYS	GSGE-012/00US	Pending	

13/488,142	US	4-Jun-12	DETERMINING THE CLINICAL SIGNIFICANCE OF VARIANT SEQUENCES	GSGE-011/00US	Pending
61/723,550	US	7-Nov-12	METHODS AND SYSTEMS FOR IDENTIFYING CONTAMINATION IN SAMPLES	GSGE-013/00US	Pending
61/723,508	US	7-Nov-12	VALIDATION OF GENETIC TESTS	GSGE-014/00US	Pending
61/784,624	US	14-Mar-13	METHODS FOR ANALYZING NUCLEIC ACIDS	GSGE-016/00US	Pending

(Remainder of the page is blank.)

809255.3